Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-01-30
2000-07-11
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, A61K 3816
Patent
active
060873272
ABSTRACT:
The compositions and methods disclosed herein utilize admixtures of neurotoxins to cause denervation which is unexpectedly more localized and of longer duration than otherwise occurs with single neurotoxins. The compositions and methods of the invention utilize neurotoxin admixtures calibrated in median paralysis units rather than LD.sub.50 s. Admixtures of neurotoxins include, but are not limited to, the botulinum serotypes A-G and tetanus toxin. The clinical benefits of the disclosed invention include: lengthening intervals between neurotoxin treatments; reducing adverse immunogenic responses to neurotoxins; and, reducing adverse diffusion-dependent side-effects of neurotoxin treatments.
REFERENCES:
patent: 5183462 (1993-02-01), Borodic
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5696077 (1997-12-01), Johnson et al.
Bandyopadhyay et al. (1987) "Role of the Heavy and Light Chains of Botulinum Neurotoxin In Neuromuscular Paralysis," J. Biol. Chem. 262:2660-2663.
Black et al. (1986) "Interaction of .sup.125 I-Labeled Botulinum Neurotoxins with Nerve Terminals. II. Autoradiographic Evidence for Its Uptake into Motor Nerves by Acceptor-Mediated Endocytosis," J. Cell Biol. 103:535-544.
Borodic et al. (1993) "Botulinum B Toxin As An Alternative to Botulinum A Toxin: A Histologic Study," Opthal. Plastic and Recons. Surg. 9: 182-190.
Gansel et al. (1987) "Distinct Sites of Action of Clostridial Neurotoxins Revealed By Double-Poisoning of Mouse Motor Nerve Terminals," Pflugers Arch. 409: 533-539.
International Search Report of International Application No. PCT/US96/08534 (Sep. 20, 1996).
Jankovic, Joseph (1994) "Botulinum Toxin In Movement Disorders," Curr. Opin. Neur. 7: 358-366.
Jankovic et al. (1991) "Therapeutic Uses of Botulinum Toxin," N. E. J. Med 324: 1186-1194.
Jankovic, J., "Therapy With Botulinum Toxin" (1994), Jankovic and Hallett eds., Marcel Dekker, Inc., New York, NY, Forward pp. vii-ix.
Maisey et al. (1988) "Involvment of the Constituent Chains of Botulinum Neurotoxins A and B in the Blockade of Neurotransmitter Release," Eur. J. Biochem 177: 683-691.
Pearce et al. (1994), "Measurement of Botulinum Toxin Activity: Evaluation of the Lethality Assay," Toxicol. and Applied Pharmacol. 128: 69-77.
Pearce et al. (1995), "The Median Paralysis Unit: A More Pharmacologically Relevant Unit of Biologic Activity for Botulinum Toxin," Toxicon 33: 217-227.
Poulain et al. (1991) "Heterologous Combinations of Heavy and Light Chains From Botulinum Neurotoxin A and Tetanus Toxin Inhibit Neurotransmitter Release in Aplysia," J. of Biol. Chem. 266: 9580-9585.
Schantz et al. (1992) "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine," Microbiol. Rev. 56: 80-99.
Sudhof, T.C. (1995) "The synaptic vesicle cycle: a cascade of protein-protein interactions", Nature 375: 645-653.
First Eric R.
Pearce L. Bruce
Engellenner Thomas J.
Russel Jeffrey E.
LandOfFree
Compositions and methods for chemodenervation using neurotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for chemodenervation using neurotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for chemodenervation using neurotoxins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-542423